Landauer (NYSE: LDR) and Integra Lifesciences (NASDAQ:IART) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, analyst recommendations, institutional ownership and profitability.

Insider & Institutional Ownership

79.6% of Landauer shares are owned by institutional investors. Comparatively, 87.6% of Integra Lifesciences shares are owned by institutional investors. 6.6% of Landauer shares are owned by company insiders. Comparatively, 21.5% of Integra Lifesciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Landauer and Integra Lifesciences’ top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Landauer N/A N/A N/A $1.92 35.00
Integra Lifesciences $992.08 million 4.17 $74.56 million $0.61 86.33

Integra Lifesciences has higher revenue and earnings than Landauer. Landauer is trading at a lower price-to-earnings ratio than Integra Lifesciences, indicating that it is currently the more affordable of the two stocks.

Dividends

Landauer pays an annual dividend of $1.10 per share and has a dividend yield of 1.6%. Integra Lifesciences does not pay a dividend. Landauer pays out 57.3% of its earnings in the form of a dividend.

Risk and Volatility

Landauer has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Integra Lifesciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Landauer and Integra Lifesciences, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Landauer 0 1 0 0 2.00
Integra Lifesciences 0 7 3 0 2.30

Integra Lifesciences has a consensus price target of $51.88, suggesting a potential downside of 1.49%. Given Integra Lifesciences’ stronger consensus rating and higher probable upside, analysts plainly believe Integra Lifesciences is more favorable than Landauer.

Profitability

This table compares Landauer and Integra Lifesciences’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Landauer 16.55% 96.20% 13.62%
Integra Lifesciences 4.52% 16.35% 6.83%

Summary

Integra Lifesciences beats Landauer on 8 of the 14 factors compared between the two stocks.

Landauer Company Profile

Landauer, Inc. is a provider of technical and analytical services to determine occupational and environmental radiation exposure. The Company is a provider of outsourced medical physics services, and a provider of radiology related medical products. The Company operates through three segments: Radiation Measurement, Medical Physics and Medical Products. The Company provides radiation dosimetry services to hospitals, medical and dental offices, universities, national laboratories, nuclear facilities and other industries. Medical physics services are provided through the Company’s Landauer Medical Physics (LMP) division. The Company uses LMP as a platform to expand into the medical physics services market, serving domestic hospitals, radiation therapy centers and imaging centers. The Company’s Medical Products segment provides medical consumable accessories used in radiology, radiation therapy and image guided surgery procedures.

Integra Lifesciences Company Profile

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions. It sells products and solutions for dural repair, precision tools and instruments, tissue ablation and neuro critical care. It also sells regenerative technology products for treating acute wounds, such as burns, and chronic wounds, including diabetic foot ulcers and surgical tissue repair. Its products are used in neurosurgery, extremity reconstruction, orthopedics and general surgery.

Receive News & Ratings for Landauer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Landauer and related companies with MarketBeat.com's FREE daily email newsletter.